Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 1,050,000 shares, a decline of 8.7% from the September 30th total of 1,150,000 shares. Based on an average daily volume of 184,900 shares, the days-to-cover ratio is currently 5.7 days. Approximately 2.5% of the company’s stock are short sold.

Insider Buying and Selling at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the sale, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares of the company’s stock, valued at $3,971,357.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. bought a new position in Aura Biosciences in the 2nd quarter worth about $119,000. American International Group Inc. raised its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Aura Biosciences in the first quarter worth $144,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the third quarter valued at $169,000. Finally, Rhumbline Advisers grew its position in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Stock Performance

AURA stock opened at $10.44 on Friday. The stock has a fifty day moving average of $9.16 and a 200-day moving average of $8.27. Aura Biosciences has a fifty-two week low of $5.99 and a fifty-two week high of $12.38. The company has a market capitalization of $517.89 million, a price-to-earnings ratio of -5.83 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Equities analysts predict that Aura Biosciences will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright lifted their target price on Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Scotiabank lifted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.